Inqanaba 2A Unyango lomhlaza wemiphunga ngo-2026: Idatha entsha ye-ELCC kwi-Neo-Adjuvant Therapy 

Inqanaba 2A unyango lomhlaza wemiphunga ngo-2026 iye yavela kakhulu, ukusuka kwiindlela zotyando-zodwa ukuya kwiindlela ezininzi ezibandakanya unyango lwe-neo-adjuvant. Izikhokelo zangoku zigxininisa ukudibanisa i-immunotherapy kunye ne-chemotherapy ngaphambi kokuhlinzwa ukuze kuphuculwe i-pathological epheleleyo impendulo (pCR) kunye nokusinda kwexesha elide. Idatha yakutsha nje evela kwi-2026 European Lung Cancer Congress (ELCC) ibalaselisa ukuba iirejimeni ezintsha, ezibandakanya i-double-checkpoint inhibitors kunye ne-immunogenic radiotherapy, ziphinda zichaze iziphumo zomhlaza wemiphunga weseli ongeyonxalenye encinci (NSCLC).

Ukuqonda iNqanaba 2A Umhlaza wemiphunga yeSeli engeNcinci

Inqanaba le-2A le-NSCLC limele ixesha elibalulekileyo kulawulo lomhlaza wemiphunga apho ithumba lihlala kwindawo kodwa linomngcipheko wesifo se-micrometastatic. Ngokwembali, uqhaqho olukhawulezileyo loqhaqho lwaba ngumgangatho wokhathalelo. Nangona kunjalo, i-oncology yanamhlanje iyaqonda ukuba unyango lwenkqubo olulawulwa phambi kotyando lunokuphelisa isifo esingabonakaliyo esisasazeka kwangoko.

Inkcazo yeNqanaba 2A ibandakanya amathumba amakhulu kune-3 cm kodwa angadluli kwi-4 cm ngaphandle kokubandakanyeka kwe-lymph node, okanye amathumba amancinci anokuhlaselwa okukhethekileyo kwendawo. Ukubekwa kweqonga okuchanekileyo kubaluleke kakhulu, njengoko kuyalela ukufaneleka kwe-neo-adjuvant protocol.

• Ubungakanani beTumor: Ngokubanzi phakathi kwe-3 cm kunye ne-4 cm yokuhlelwa kwe-T2a N0 M0.
• Isimo se-Lymph Node: Ngokuqhelekileyo akukho metastasis yengingqi ye-lymph node (N0), nangona ukubandakanyeka kwe-microscopic kuyinkxalabo.
• Ukuphinda ubekho: Izigulane zithathwa njengabaviwa ukuze basuswe ngokupheleleyo ngotyando (i-R0 resection).

Injongo yonyango ayikokususwa kwe-tumor kuphela kodwa kukuqinisekisa ukusinda kwexesha elide lokungenasifo (DFS) kunye nokusinda ngokubanzi (OS). Ukutshintshela kunyango lwangaphambi kotyando lujolise ekwehliseni ithumba, ukwenza utyando lube lula kwaye lusebenze ngakumbi.

Ukutshintsha ukusuka kwiAdjuvant ukuya kwiNeo-Adjuvant Therapy

Kwiminyaka emininzi, i-adjuvant chemotherapy (enikwe emva kotyando) yayiyinto eqhelekileyo. Ngelixa yayibonelela ngeenzuzo ezithobekileyo, ukuthotyelwa kwakusoloko kungalunganga ngenxa yemicimbi yokuchacha emva kotyando. Unyango lwe-neo-adjuvant, olunikwa phambi kotyando, lujongana noku ngokunyanga isigulana ngexa sisalungile.

Ulingo lwakutsha nje lweklinikhi lubonise ukuba iindlela ze-neo-adjuvant zivelisa amaxabiso aphezulu e-pCR xa kuthelekiswa noseto lwe-adjuvant. Ukufezekisa i-pCR, apho kungekho ziseli zomhlaza ezisebenzayo zihlala kumzekelo wotyando, zihambelana kakhulu neziphumo eziphuculweyo zexesha elide. Olu tshintsho lweparadigm lusembindini wenkangeleko yonyango ka-2026.

Ngapha koko, unyango lwe-neo-adjuvant luvumela oogqirha ukuba bavavanye impendulo yethumba ngexesha lokwenyani. Ukuba i-tumor ayiphenduli kwi-regimen yokuqala, unyango lunokulungelelaniswa ngaphambi kokwenza utyando, ukuphepha iinkqubo ezingenamsebenzi kwiimeko zezifo ezinobundlobongela.

I-2026 ye-ELCC yokuPhumeza kwi-Neo-Adjuvant Strategies

I-2026 European Lung Cancer Congress (ELCC) yasebenza njengeqonga elibalulekileyo lokutyhila idatha yenguqu kwi-NSCLC ehlaziywayo. Izifundo ezininzi ezithiwe thaca e-Copenhagen zisete iibenchmarks ezintsha zento ebandakanya ukhathalelo olusemgangathweni lweSigaba 2A kunye nesifo esiqhubela phambili ekuhlaleni.

Enye yezona ngxoxo zibalulekileyo zijikeleze imida yomqolo we "PD-1 inhibitor kunye nechemotherapy". Ngelixa izifundo ezifana ne-CheckMate 816 kunye ne-KEYNOTE-671 ziseke le ndibaniselwano, inxalenye enkulu yezigulane zisasilela ukufikelela kwi-pCR. Uphando olutsha lujolise ekomelezeni ezi rejimeni ngokukhuselekileyo.

Iingcaphephe ze-ELCC 2026 ziqaqambise ukuba ikamva lilele kwindibaniselwano eyenzelwe umntu. Oku kubandakanya ukongeza ii-agent zenoveli ezinjenge-bispecific antibodies okanye ukudibanisa unyango lwasekhaya olufana ne-radiotherapy ukomeleza ukusebenza komzimba ngaphambi kokuba imela ichukumise ulusu.

Isifundo se-Neo-RISE Lung: iParadigm eNtsha

Inkcazo-ntetho ebalaseleyo kwi-ELCC 2026 yayiyidatha yokuqala evela kuphononongo lwe-Neo-RISE Lung. Olu lingo lutsha luphonononge indlela yokwenza kathathu: i-radiotherapy ye-immunogenic elandelwa yi-PD-1/VEGF bispecific antibody (ivonescimab) kunye nechemotherapy.

Ingqiqo emva kolu yilo yi-synergistic. I-Radiotherapy yenza ukufa kweeseli ze-immunogenic, ukukhulula ii-antigens ze-tumor. I-antibody ye-bispecific emva koko ivimba iindawo zokujonga izifo ezimbini ngaxeshanye ngelixa inqanda i-angiogenesis ngokucinezelwa kwe-VEGF. Le “punch-one-two” inceda amajoni omzimba ngempumelelo ngakumbi kunechemotherapy kuphela.

• Inqanaba leNjongo yokuPhendula (ORR): Uphononongo luchaze i-ORR enomtsalane ye-100% kwiqela elivavanyiweyo.
• Impendulo eGqibeleleyo yePathological (pCR): Amaxabiso afikelele kuma-55.1%, aphezulu kakhulu kunolawulo lwembali lwe ~24%.
• Impendulo engundoqo yePathological (MPR): Ifunyenwe kwi-79.3% yezigulane.
• Ukwehlisa: I-88.2% yezigulane ziye zafumana ukuhla kwe-tumor, ukuququzelela uqhaqho olulula.

Okubaluleke kakhulu, zonke izigulana eziye zatyandwa zafumana i-R0 resection, okuthetha ukuba akukho ziseli zomhlaza ezishiywe emaphethelweni. Le datha iphakamisa ukuba kwizigulana zeSigaba 2A, ukongeza i-radiotherapy kunye ne-biological-targeting biologics ingaba ngumgangatho omtsha weempawu eziphezulu zomngcipheko.

I-KEYNOTE-671 Idatha yexesha elide: Amandla e-Perioperative Immunotherapy

Elinye ilitye lembombo le-ELCC ye-2026 yayiluhlalutyo oluhlaziyiweyo lwexesha elide lolingo lwe-KEYNOTE-671. Olu phononongo lweSigaba sesi-3 luvavanye i-pembrolizumab edityaniswe nechemotherapy njengonyango lwe-neo-adjuvant, lulandelwa yi-adjuvant pembrolizumab monotherapy.

Iziphumo zamva nje, ezisekelwe kwiinyanga ezingaphezu kwe-60 zokulandelela, ziqinisekisile ukuba inzuzo ye-perioperative immunotherapy iqinile. Okubaluleke kakhulu, idatha ilungelelanise izigulana ngokwempendulo yazo ye-pathological, enikezela ngemibono engathandekiyo koogqirha abanyanga isifo seSigaba 2A.

Kwanezigulane ezingazange zifezekise impendulo epheleleyo ye-pathological (non-pCR) ifumene inzuzo ebalulekileyo yokusinda kwisiganeko (EFS). Umlinganiselo wengozi ye-EFS kwiqela le-non-pCR yayingu-0.69, ebonisa ukunciphisa i-31% kwingozi yokuphindaphinda okanye ukufa xa kuthelekiswa ne-placebo.

Kwabo baphumelele i-pCR, iziphumo zazikhethekile, kunye ne-5-year EFS rate ye-81%. Oku kuqinisa uluvo lokuba ngelixa i-pCR inamandla okumakisha i-surrogate, i-systemic effect ye-immunotherapy ikhusela izigulana kungakhathaliseki ubunzulu bempendulo ye-pathological.

UNyango ekuJoliswe kulo kuMqhubi-oGuquliweyo kwiSigaba se-2A soMhlaza wemiphunga

Ayiyiyo yonke iNqanaba 2A yomhlaza wemiphunga eqhutywa ziindlela ezifanayo. Ngokumalunga ne-15-20% yezigulane zaseNtshona kwaye ukuya kuthi ga kwi-50% yezigulane zase-Asia zineenguqu zabaqhubi ezifana ne-EGFR okanye i-ALK. Kwaba bantu, i-immunotherapy yodwa isenokungabi sesona sicwangciso sifanelekileyo se-neo-adjuvant.

I-ELCC ye-2026 ibonelele ngohlaziyo olubalulekileyo kwiindlela zonyango ezijoliswe kuzo kwi-perioperative setting. Ulingo lwe-ADAURA lwalusele luseke i-osimertinib njengomgangatho wonyango lwe-adjuvant kwi-EGFR-mutated NSCLC. Idatha entsha ngoku ityhala ezi arhente kwindawo ye-neo-adjuvant.

Ukuguqulwa kwe-EGFR kunye ne-TOP Study Insights

Ngelixa uphononongo lwe-TOP lujolise ikakhulu kwisifo se-metastatic esiphezulu, iimpembelelo zaso kunyango lwakwangoko zinzulu. Uphononongo luphande i-osimertinib edibene ne-chemotherapy ngokuchasene ne-osimertinib yodwa kwizigulane ezinokuguqulwa kwe-EGFR kunye nokuguqulwa kwe-TP53 efanayo.

I-TP53 co-mutations iyaziwa ngokunika ukuchasana ne-EGFR tyrosine kinase inhibitors (TKIs). Uphononongo lwe-TOP lubonise ukuba ukongeza i-chemotherapy kwi-osimertinib kuphindwe kabini ukusinda ngaphandle kokuqhubekela phambili (PFS) kweli qela lisemngciphekweni omkhulu. Oku kuphakamisa ukuba kwi-Stage 2A izigulane ezine-EGFR/TP53 co-mutations, indlela yokudibanisa inokuba yimfuneko nakwimeko yonyango.

Oogqirha bayaxoxa ngoku ukuba bathathe i-chemo-immunotherapy okanye indibaniselwano ye-chemo-TKI yonyango lwe-neo-adjuvant kubantu abaqhuba kakuhle. Imvumelwano ihambela kwizigqibo ezikhokelwa yi-molecularly kunendlela enye ye-immunotherapy.

I-ALK Isifo Esilungileyo: Impembelelo yoFundo lwe-ALINA

Kwizigulane ezine-ALK rearrangements, uphononongo lwe-ALINA lube ngumtshintshi womdlalo. Ibonise ukuba i-adjuvant alectinib iphucula kakhulu i-DFS xa kuthelekiswa ne-chemotherapy-based based chemotherapy. Nangona idatha ye-neo-adjuvant ikhulile ngaphantsi kunedatha ye-adjuvant, ukusebenza kwe-alectinib ekunciphiseni amathumba kwangaphambili kuphandwa ngenkuthalo.

Ngo-2026, kugxininiswa ekumiseleni elona xesha lifanelekileyo lonyango ekujoliswe kulo. Ngaba kufuneka inikwe kuphela emva kokuhlinzwa, okanye kufuneka "sandwich" indlela (neo-adjuvant + adjuvant) yamkelwe? Izibonakaliso zakwangoko zibonisa ukuba unyango olujoliswe ngaphambili lunokwenza lula utyando oluncinci, lugcina ukusebenza kwemiphunga kwizigulane zeSigaba 2A.

Uhlalutyo lokuthelekisa kwiiNdlela zoNyango

Ukukhetha ekunene isigaba 2a unyango lomhlaza wemiphunga kufuna ukuvavanya iingenelo kunye nobungozi beendlela ezahlukeneyo. Le theyibhile ilandelayo ithelekisa amacebo aphambili ekuxoxwe ngawo kwi-ELCC ka-2026.

Lo mzekeliso ugxininisa ukuba "ubukhulu obunye abulingani zonke." Ubukho beempawu ezithile zofuzo okanye ubuninzi bethumba bunokumisela ukuba isigulane sizuza ngakumbi kwi-chemo-immunotherapy eqhelekileyo, irejimeni yovavanyo oluqinisiweyo, okanye ii-arhente ezijoliswe kuzo.

IiPros and Cons of Neo-Adjuvant Approaches

Ukwamkela unyango lwe-neo-adjuvant kwiNqanaba lesi-2A lomhlaza wemiphunga lunika uncedo olwahlukileyo kodwa lukwazisa imingeni emitsha ekufuneka ilawulelwe amaqela ahlukeneyo.

• Izinto eziluncedo:
  • Ulawulo Lwenkqubo Kwangethuba: Unyanga i-micrometastases ngokukhawuleza, ukunciphisa umngcipheko wokuphindaphinda okude.
  • KuVavanyo lokuSensitivity lweVivo: Ivumela oogqirha ukuba babone ukuba ithumba liyancipha, linikezela ngolwazi lwe-prognostic.
  • Ukuphucula ukuSetka kwakhona: Ngaba ukwehlisa amathumba, ukuguqula iimeko ezinokuthi zihlaziywe emdeni ukucima ukukhutshwa kwe-R0.
  • Ukuthotyelwa okuphezulu: Izigulane zinyamezela unyango lwe-systemic bhetele ngaphambi kokuhlinzwa kunexesha lokubuyisela.
• Izinto ezingeloncedo:
  • Ukulibazisa kuTyando: Unyango luthatha iiveki, nto leyo enokubangela unxunguphalo okanye ukuqhubela phambili okunokwenzeka kwiimeko ezinobundlobongela obunqabileyo.
  • Ukuntsonkotha kotyando: Ukuvuvukala okanye i-fibrosis ebangelwa unyango ngamanye amaxesha inokwenza ukuba i-dissection ibe nzima ngakumbi koogqirha.
  • Imingcipheko yetyhefu: Iziganeko ezimbi ezinxulumene ne-immune (irAEs) zinokuthi zenzeke ngaphambi kokusebenza, ezinokuthi zibe nzima ukuphelisa i-anesthesia okanye ukuphulukiswa kwesilonda.

Nangona le mingeni, ubungqina obuninzi obuvela kwi-2026 buxhasa inzuzo eseleyo yezicwangciso ze-neo-adjuvant kwizigulane ezifanelekileyo ze-Stage 2A. Undoqo ulele ekukhetheni isigulane ngononophelo kunye nolungelelwaniso olomeleleyo lweenkqubo ezininzi.

ISikhokelo seNyathelo ngeNyathelo kuLawulo lweSigaba 2A sanamhlanje

Ukuhamba kuhambo lonyango lweSigaba 2A somhlaza wemiphunga ngo-2026 kubandakanya inkqubo eyakhiweyo, enezinto ezininzi. Nantsi indlela yokusebenza ngokubanzi esekwe kwizenzo ezilungileyo zangoku.

• INyathelo 1: Ukubekwa ngokuBanzi kunye neProfayili yeMolekyuli
  
  Ngaphambi kwaso nasiphi na isigqibo sonyango, izigulane zifumana i-PET-CT scans kunye ne-brain MRI ukulawula i-metastasis ekude. Okubaluleke kakhulu, i-tissue biopsy kufuneka ivavanyelwe i-EGFR, ALK, ROS1, kunye ne-PD-L1 intetho. Eli nyathelo limisela ukuba isigulane singena kwi-immunotherapy okanye kwindlela yonyango ekujoliswe kuyo.
• Inyathelo lesi-2: Uphononongo lweqela leeNgxoxo ezininzi (MDT).
  
  Iqela elibandakanya oogqirha botyando lwesifuba, ii-oncologists zonyango, i-radiation oncologists, kunye neengcali zezifo zihlola imeko. Bavavanya ukwenzeka kwakhona kwaye baxoxe ngeenzuzo ezinokubakho zonyango lwe-neo-adjuvant ngokuchasene notyando lwangaphambili olusekwe kwidatha ye-ELCC yamva nje.
• Inyathelo lesi-3: Ukuqaliswa kwe-Neo-Adjuvant Therapy
  
  Ukuba kufanelekile, isigulane siqala irejimeni ekhethiweyo. Kwizigulane ezingenayo umqhubi, oku kuqhelekile ukuba yi-3-4 imijikelezo ye-platinum-doublet chemotherapy kunye ne-PD-1/PD-L1 inhibitor. Kwiimeko ezisemngciphekweni omkhulu, ulingo lwezonyango olubandakanya izilwa-buhlungu ze-bispecific okanye unyango lweradiyo lunokubonelelwa.
• Inyathelo lesi-4: Ukubuyisela kwakhona kunye noCwangciso lotyando
  
  Emva kokugqiba imijikelo ye-neo-adjuvant, ukuphinda umfanekiso wenziwa ukuvavanya impendulo. Ukuba isifo sizinzile okanye siphendule, utyando lucwangciswe ngokuqhelekileyo kwiiveki ezi-3-6 emva komthamo wokugqibela we-immunotherapy ukuvumela ukubuyiswa komzimba.
• Inyathelo lesi-5: Utyando lokuTyeka kunye noVavanyo lwePathological
  
  Ugqirha wenza i-lobectomy okanye i-segmentectomy kunye ne-lymph node dissection. I-pathologist ihlola i-specimen ukumisela i-Major Pathological Response (MPR) okanye i-Pathological Complete Response (pCR), ekhokela unyango olongezelelweyo.
• Inyathelo lesi-6: Ukudityaniswa kwe-Adjuvant
  
  Ngokuxhomekeke kwisicwangciso sokuqala kunye neziphumo ze-pathological, izigulane zingaqhubeka ne-adjuvant immunotherapy (umzekelo, i-pembrolizumab) ukuya kuthi ga kunyaka okanye ukutshintshela kunyango olujoliswe kuyo (umzekelo, i-osimertinib) ukuba uguquko lufunyenwe. Le ndlela "yeperioperative" iqinisekisa ukhuseleko oluqhubekayo malunga nokuphindaphinda.

Indima yoHlolo lweZifo eziNcinane eziSisalelayo (MRD).

Isixhobo esavelayo ngo-2026 kukusetyenziswa kwe-tumor DNA (ctDNA) ukubeka iliso kwi-Minimal Residual Disease (MRD). Le teknoloji ibhaqa izixa ezincinci zomhlaza weDNA egazini elingenakubonwa ngumfanekiso.

Uphononongo oluthiwe thaca kwiinkomfa zakutsha nje lucebisa ukuba ukucocwa kwe-ctDNA ngexesha lonyango lwe-neo-adjuvant singqikelelo esinamandla sokusinda kwexesha elide. Ngokuchaseneyo, i-ctDNA eqhubekayo emva kotyando inokuchonga izigulane ezidinga unyango lwe-adjuvant olwandisiweyo. Ngelixa ingekanyanzeliswa kwihlabathi liphela, ukubekwa esweni kwe-MRD ngokukhawuleza kuba licandelo eliqhelekileyo le-oncology echanekileyo kwiSigaba 2A somhlaza wemiphunga.

Umzekelo, idatha kwi-cadonilimab (i-PD-1/CTLA-4 bispecific antibody) ibonise ukuba izigulana eziye zafumana imvume ye-ctDNA ziye zaphila ixesha elide. Le luphu yengxelo yeemolekyuli ivumela uhlengahlengiso lonyango oluguquguqukayo, ukusuka kwiiprotocol zexesha elimiselweyo.

Iingqwalasela zeklinikhi kuBantu abaKhethekileyo

Ukunyanga inqanaba 2A umhlaza wemiphunga awufani kubo bonke abantu. Abemi abathile bafuna iindlela ezilungiselelwe ukulungelelanisa ukusebenza kakuhle nokhuseleko.

Izigulana eziDala kunye nabo banesimo esibi sokusebenza

Abantu abadala abadala okanye izigulana ezinezigulo zidla ngokusokola ngobutyhefu bedosi epheleleyo ye-chemo-immunotherapy. Ulingo lwe-ETOP ADEPPT kunye nezifundo ezifanayo ziye zaphonononga iirejimeni zoxinzelelo oluncitshisiweyo okanye unyango olujoliswe yiarhente enye kula maqela.

Ngo-2026, imeko isiya “ekuncipheni” kwizigulana ezibuthathaka. Oku kunokubandakanya ukusebenzisa i-immunotherapy monotherapy ukuba i-PD-L1 ibonakaliso iphezulu, okanye ukukhetha ii-arhente ezijoliswe kuyo ukuba kukho utshintsho lomqhubi, ukuphepha iziphumo ezibi ze-platinum chemotherapy. Injongo ihlala yonyango, kodwa indlela iyalungiswa ukuqinisekisa ukuba isigulane sinokugqiba unyango.

Izigulana ezineMetastases yeBrain

Ngelixa iNqanaba 2A lithetha ukuba akukho kusasazeka okude, i-metastases yobuchopho bomlingo ngamanye amaxesha inokufumaneka xa kujongwa ngokweenkcukacha. Isizukulwana esitsha se-TKIs esifana ne-osimertinib kunye ne-alectinib zinenkqubo egqwesileyo ye-nervous system (CNS) yokungena.

Kwizigulana ezinomda weemetastases zobuchopho ezifunyenwe ngexesha lesiteji, unyango lwenkqubo kunye namachiza asebenzayo e-CNS luhlala lubekwe phambili phambi konyango lwengqondo lwasekhaya. Izifundo ze-ARTS kunye ne-ALINA zomeleze ukuzithemba ekunyangeni isifo senqanaba lakwangoko kunye neearhente ezikhusela ingqondo, ukunciphisa imfuno yemitha ye-cranial ehlaselayo kwezinye iimeko.

Izikhokelo zexesha elizayo kunye noPhando oluqhubekayo

Imbonakalo yomhlaba ye isigaba 2a unyango lomhlaza wemiphunga iyaguquguquka. Njengoko sihamba ngo-2026, iindawo ezininzi zophando zithembisa ukuqhubeka nokucokisa iziphumo. Ukudityaniswa kobukrelekrele bokwenziwa kwiradiomics kunceda ukuqikelela ukuba zeziphi izigulana eziya kusabela kunyango lwe-neo-adjuvant phambi kokuba unyango luqale.

Ukongeza, uphuhliso lwesizukulwana esilandelayo se-antibody-drug conjugates (ADCs) luvula iingcango ezintsha. Iimvavanyo ezibandakanya i-HER3-directed ADCs kunye ne-TROP2-ejoliswe kwii-agent zibonisa isithembiso kwisimo se-neo-adjuvant, ezinokuthi zinike iinketho kwizigulane ezingaphenduliyo kwi-immunotherapy eqhelekileyo.

Ingqikelelo "yonyango olupheleleyo lwe-neoadjuvant" nayo ifumana amandla. Le ndlela iphelisa unyango lwe-adjuvant ngokupheleleyo, ihambisa lonke unyango lwenkqubo ngaphambi kokuhlinzwa. Idatha yangaphambili ibonisa ukuba oku kunokwenza lula uhambo lwesigulane kunye nokuphucula ukuthotyelwa, nangona idatha yokusinda kwexesha elide isakhula.

Ukubaluleka kovavanyo lwezonyango

Ukunikezelwa ngokukhawuleza kwemigangatho yonyango, ukubhaliswa kwizilingo zeklinikhi kukhuthazwa kakhulu kwizigulane zeSigaba 2A. Iimvavanyo ezifana ne-Galaxy-L-01, ukuphanda i-garsorasib edityaniswe ne-anlotinib yokuguqulwa kwe-KRAS G12C, inikezela ukufikelela kunyango oluphambili ngaphambi kokuba lufumaneke ngokubanzi.

Ukuthatha inxaxheba kolu phando akuncedi kuphela isigulana ngasinye kodwa kunegalelo kwisiseko solwazi lwehlabathi, kukhawulezisa ukufunyanwa konyango. Oogqirha bayabongozwa ukuba baxoxe ngokufaneleka kovavanyo kunye nesigulana ngasinye esifanelekileyo xa sixilongwa.

Isiphelo: Ixesha elitsha leThemba leNqanaba 2A loMhlaza wemiphunga

Unyaka ka-2026 uphawula utshintsho oluqinisekileyo kulawulo lweSigaba 2A somhlaza wemiphunga ongeyonxalenye encinci. Zihambile iintsuku uqhaqho lwaba lukuphela kwempendulo. Namhlanje, isigaba 2a unyango lomhlaza wemiphunga yinto enzima, umzamo we-multimodal udibanisa ukuchaneka kwonyango olujoliswe kuyo, amandla e-immunotherapy, kunye nexesha elicwangcisiweyo lokungenelela kwe-neo-adjuvant.

Idatha evela kwi-ELCC ka-2026, ngokukodwa malunga nesifundo se-Neo-RISE Lung kunye neziphumo zexesha elide ze-KEYNOTE-671, iqinisekisa ukuba sinokufikelela kumazinga aphezulu okunyanga kunanini ngaphambili. Ngokwenza unyango olulolwakho olusekwe kwiiprofayili zemolekyuli kunye nokuxhasa indibaniselwano yenoveli efana ne-bispecific antibodies kunye ne-radiotherapy ye-immunogenic, oogqirha baguqula iimeko ebezikhe zaba nzima zibe ngamabali empumelelo.

Kwizigulana kunye neentsapho, oku kuthetha ikamva elinokhetho oluninzi, amathuba angcono okuphila, kunye nokuphucula umgangatho wobomi. Njengoko uphando luqhubeka nokutyhila ubunzima bebhayoloji yomhlaza wemiphunga, umkhondo ukhomba kwindlela esebenza ngakumbi, enetyhefu encinci, kunye neendlela zokhathalelo lomntu kakhulu. Intsebenziswano phakathi koogqirha botyando, ioncologists, kunye nabaphandi ihlala isisiseko sale nkqubela phambili, iqinisekisa ukuba isigulana ngasinye seSigaba se-2A sifumana elona thuba lilungileyo lokunyanga.